Mirae Asset Global Investments Co. Ltd. Purchases 404 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 3.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,898 shares of the company’s stock after purchasing an additional 404 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Keros Therapeutics were worth $513,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of Keros Therapeutics by 356.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,460 shares of the company’s stock worth $138,000 after buying an additional 2,702 shares during the period. Arizona State Retirement System bought a new position in Keros Therapeutics in the 4th quarter valued at $231,000. TD Asset Management Inc increased its stake in Keros Therapeutics by 100.0% in the third quarter. TD Asset Management Inc now owns 36,200 shares of the company’s stock worth $1,154,000 after purchasing an additional 18,100 shares during the period. Swiss National Bank increased its stake in Keros Therapeutics by 4.8% in the third quarter. Swiss National Bank now owns 45,600 shares of the company’s stock worth $1,454,000 after purchasing an additional 2,100 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of Keros Therapeutics by 466.7% during the third quarter. SG Americas Securities LLC now owns 47,183 shares of the company’s stock worth $1,504,000 after purchasing an additional 38,857 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 3.6 %

Shares of NASDAQ KROS opened at $54.19 on Friday. Keros Therapeutics, Inc. has a 12-month low of $27.02 and a 12-month high of $73.00. The stock’s fifty day simple moving average is $63.61 and its two-hundred day simple moving average is $47.66. The stock has a market capitalization of $1.95 billion, a PE ratio of -10.42 and a beta of 1.26.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Friday, March 1st. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $0.14 million for the quarter. During the same quarter in the prior year, the firm posted ($1.09) earnings per share. On average, equities analysts predict that Keros Therapeutics, Inc. will post -5.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. William Blair restated an “outperform” rating on shares of Keros Therapeutics in a report on Wednesday, February 21st. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Friday, March 1st. Wedbush reissued an “outperform” rating and issued a $86.00 price objective on shares of Keros Therapeutics in a research note on Thursday, February 29th. Truist Financial restated a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a report on Wednesday, March 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $105.00 price target on shares of Keros Therapeutics in a research report on Wednesday, March 27th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $86.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.